Maravai LifeSciences
MRVI
185 hedge funds and large institutions have $769M invested in Maravai LifeSciences in 2024 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 66 increasing their positions, 63 reducing their positions, and 57 closing their positions.
737% more call options, than puts
Call options by funds: $2.11M | Put options by funds: $252K
5% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 63
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.52% less ownership
Funds ownership: 101.81% → 99.29% (-2.5%)
15% less funds holding
Funds holding: 217 → 185 (-32)
36% less capital invested
Capital invested by funds: $1.2B → $769M (-$429M)
53% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 57
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$20.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$17.8M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$11.1M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$6.84M |
| 5 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
+$5.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1WCM
12 West Capital Management
New York
|
-$15.6M |
| 2 |
Millennium Management
New York
|
-$15.6M |
| 3 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$14.9M |
| 4 |
ClearBridge Investments
New York
|
-$8.69M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.53M |
MRVI Hedge Fund Activity: Q4 2024 in Review
185 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q4 2024, worth a combined $769M — down 36% from $1.2B a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of MRVI and 27 opened new positions — a net loss of 30 holders — while 63 trimmed existing stakes and 66 added.
The largest buyer was Alyeska Investment Group, adding an estimated $20.3M. The largest seller was 12 West Capital Management, cutting an estimated $15.6M.
- 185 institutional investors held Maravai LifeSciences (MRVI) as of Q4 2024, down from 217 in Q3 2024.
- Funds reported $769M of Maravai LifeSciences stock for Q4 2024, down 36% quarter-over-quarter.
- 27 funds opened new Maravai LifeSciences positions in Q4 2024 and 57 closed out, a net change of -30 holders.
- The largest Maravai LifeSciences buyer in Q4 2024 was Alyeska Investment Group, an estimated $20.3M added.
- The largest Maravai LifeSciences seller in Q4 2024 was 12 West Capital Management, an estimated $15.6M sold.
Based on aggregated 13F filings for Q4 2024.